Krystal Biotech. has filed a patent for recombinant nucleic acids containing polynucleotides that encode an immunomodulatory polypeptide, such as IL-2 or IL-12. The patent also covers viruses, compositions, and formulations containing these nucleic acids, as well as methods for using them in cancer treatment. The claim has been canceled. GlobalData’s report on Krystal Biotech gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Krystal Biotech Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Krystal Biotech, Oncolytic viruses was a key innovation area identified from patents. Krystal Biotech's grant share as of September 2023 was 25%. Grant share is based on the ratio of number of grants to total number of patents.

Recombinant nucleic acids for immunomodulatory polypeptides for cancer treatment

Source: United States Patent and Trademark Office (USPTO). Credit: Krystal Biotech Inc

A recently filed patent (Publication Number: US20230241251A1) describes a pharmaceutical composition that includes a replication defective herpes simplex virus (HSV) genome and one or more heterologous polypeptides for stimulating an immune response. The recombinant HSV genome encodes human cytokines or human chemokines, which are proteins that play a role in immune system regulation. The composition also includes a pharmaceutically acceptable excipient, which is a substance used as a carrier or vehicle for the active ingredients.

The patent claims specify various aspects of the pharmaceutical composition. For example, claim 131 states that the recombinant HSV genome does not have an inactivating mutation in an ICP27 gene. Claim 132 mentions that the recombinant HSV genome can be either HSV-1 or HSV-2. Claim 134 states that the recombinant HSV genome may have an inactivating mutation in certain herpes simplex virus genes. Claim 139 lists several human cytokines and human chemokines that can be included in the composition, such as Interleukins, Tumor Necrosis Factor alpha, and Interferon gamma.

The patent also describes the suitability of the pharmaceutical composition for various routes of administration, including topical, oral, intravenous, and inhaled. It specifies that the composition is not a vaccine and does not encode an antigen. Additionally, claim 146 highlights that the human cytokine used in the composition is not Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF). Claim 157 mentions that the composition can be used for cancer treatment.

Overall, the patent presents a pharmaceutical composition that utilizes a replication defective herpes simplex virus genome to deliver human cytokines or human chemokines for stimulating an immune response. The composition can be administered through various routes and has potential applications in cancer treatment.

To know more about GlobalData’s detailed insights on Krystal Biotech, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies